SG Americas Securities LLC reduced its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 61.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,713 shares of the biopharmaceutical company’s stock after selling 37,175 shares during the period. SG Americas Securities LLC’s holdings in Amicus Therapeutics were worth $341,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Great West Life Assurance Co. Can boosted its holdings in Amicus Therapeutics by 40.2% in the 3rd quarter. Great West Life Assurance Co. Can now owns 14,445 shares of the biopharmaceutical company’s stock worth $212,000 after buying an additional 4,145 shares during the period. California Public Employees Retirement System boosted its holdings in Amicus Therapeutics by 2.4% in the 3rd quarter. California Public Employees Retirement System now owns 181,000 shares of the biopharmaceutical company’s stock worth $2,729,000 after buying an additional 4,200 shares during the period. Strs Ohio purchased a new stake in Amicus Therapeutics in the 3rd quarter worth approximately $102,000. Nationwide Fund Advisors lifted its stake in Amicus Therapeutics by 5.6% in the 3rd quarter. Nationwide Fund Advisors now owns 178,212 shares of the biopharmaceutical company’s stock worth $2,687,000 after purchasing an additional 9,503 shares in the last quarter. Finally, Birchview Capital LP purchased a new stake in Amicus Therapeutics in the 3rd quarter worth approximately $151,000.
In other news, SVP Daphne Quimi sold 8,750 shares of the firm’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $15.00, for a total value of $131,250.00. Following the sale, the senior vice president now directly owns 73,082 shares in the company, valued at approximately $1,096,230. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jay Barth sold 5,000 shares of the stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $15.05, for a total transaction of $75,250.00. Following the completion of the transaction, the insider now directly owns 90,409 shares of the company’s stock, valued at $1,360,655.45. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 207,870 shares of company stock worth $3,066,112. Company insiders own 3.40% of the company’s stock.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.11). Amicus Therapeutics had a negative return on equity of 71.06% and a negative net margin of 769.03%. The company had revenue of $14.73 million for the quarter, compared to the consensus estimate of $14.50 million. analysts forecast that Amicus Therapeutics, Inc. will post -1.26 earnings per share for the current fiscal year.
Several analysts have recently weighed in on FOLD shares. Leerink Swann raised their price objective on shares of Amicus Therapeutics from $20.00 to $24.00 and gave the company an “outperform” rating in a research report on Thursday, February 8th. Zacks Investment Research cut shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, December 19th. Cowen reissued a “buy” rating and issued a $22.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 10th. BidaskClub raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, January 15th. Finally, Robert W. Baird set a $20.00 target price on shares of Amicus Therapeutics and gave the company a “buy” rating in a research note on Wednesday, February 7th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. Amicus Therapeutics currently has a consensus rating of “Buy” and an average target price of $19.06.
Amicus Therapeutics Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.